Vera Therapeutics (VERA) Stock
Clinical biotech developing immune and respiratory treatments. Here's the price, business snapshot, and what's worth knowing about Vera Therapeutics in August 2026.
Vera Therapeutics Inc (VERA) is a clinical-stage biotechnology company developing novel therapies targeting immune-mediated and respiratory conditions. With a market capitalisation of around US$1.94bn, it attracts attention from investors interested in innovation-driven small caps. The company’s value largely depends on pipeline progress, clinical trial results and regulatory milestones, so share price can be volatile. For long-term investors, key considerations include the strength of the balance sheet, upcoming data readouts, partner and licensing agreements, and competitive landscape. Vera may offer upside if trials succeed, but there is significant risk if development programmes encounter delays or negative results. This summary provides general, educational information — not personalised investment advice. Investors should review company filings, seek professional advice if needed and only invest money they can afford to risk, because biotech stocks can experience wide price swings and outcomes are uncertain.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying VERA's stock with a target price of $71.95, indicating strong growth potential.
Financial Health
VERA Therapeutics is showing positive financial performance with strong cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage focus
Pipeline milestones and trial readouts are primary value drivers; successful data can boost prospects, though outcomes are uncertain and can move prices sharply.
Scientific innovation
Investment interest often centres on novel approaches and partnerships, but scientific promise does not guarantee commercial success.
Market dynamics
Competition, regulatory environment and financing needs shape the opportunity; consider diversification since biotech stocks can be volatile.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
